{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:52:06Z","timestamp":1775091126132,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the benefit of adjuvant treatments, such as chemoradiotherapy (CRT) and chemotherapy (CTx), compared with no adjuvant treatment (No-AT) in resected gallbladder (GB) cancer patients, 151 patients were analyzed: 98 (64.9%) patients received adjuvant treatment with CRT (n\u2009=\u200959, 39.1%) or CTx (n\u2009=\u200939, 25.8%), and the remaining 53 (35.1%) did not (No-AT). The clinicopathological factors, patterns of failure, locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS) and overall survival (OS) were compared among the three groups according to tumor stage. In patients with T2-3N0M0 stage disease, the incidences of locoregional recurrence and distant recurrence and 5-year LRFS, RFS and OS rates were not significantly different among the No-AT, CTx, and CRT groups (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05 each). In those with T2-3N1-2M0 stage disease, the incidences of locoregional recurrence (11.4%, 78.1%, and 68.4%, respectively) and distant recurrence (42.8%, 73.9% and 66.7%, respectively) in the CRT group were significantly lower than those in the No-AT and CTx groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), and the CRT group had significantly higher 5-year LRFS (82,1%, 26.8%, and 19.0%), RFS (53.3%, 11.6% and 16.7%) and OS rates (64.0%, 22.7% and 4.3%) than the CTx and No-AT groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 each). Therefore, adjuvant CRT may improve the LRFS and RFS and subsequently improve OS in lymph node-positive resected GB cancer.<\/jats:p>","DOI":"10.1038\/s41598-019-48099-z","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T10:02:28Z","timestamp":1565690548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-3385","authenticated-orcid":false,"given":"Tae Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Myung","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Sang","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hee","family":"Youn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4079-2503","authenticated-orcid":false,"given":"Sang Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Sik","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Jae","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"48099_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11605-007-0109-z","volume":"11","author":"JS Park","year":"2007","unstructured":"Park, J. S. et al. Actual recurrence patterns and risk factors influencing recurrence after curative resection with stage II gallbladder carcinoma. J Gastrointest Surg 11, 631\u2013637, https:\/\/doi.org\/10.1007\/s11605-007-0109-z (2007).","journal-title":"J Gastrointest Surg"},{"key":"48099_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s11605-009-1140-z","volume":"14","author":"WS Kim","year":"2010","unstructured":"Kim, W. S. et al. Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma. J Gastrointest Surg 14, 679\u2013687, https:\/\/doi.org\/10.1007\/s11605-009-1140-z (2010).","journal-title":"J Gastrointest Surg"},{"key":"48099_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000339695","volume":"83","author":"SJ Jung","year":"2012","unstructured":"Jung, S. J. et al. Patterns of initial disease recurrence after resection of biliary tract cancer. Oncology 83, 83\u201390, https:\/\/doi.org\/10.1159\/000339695 (2012).","journal-title":"Oncology"},{"key":"48099_CR4","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/cncr.11699","volume":"98","author":"WR Jarnagin","year":"2003","unstructured":"Jarnagin, W. R. et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98, 1689\u20131700, https:\/\/doi.org\/10.1002\/cncr.11699 (2003).","journal-title":"Cancer"},{"key":"48099_CR5","first-page":"1609","volume":"51","author":"M Aramaki","year":"2004","unstructured":"Aramaki, M. et al. Factors influencing recurrence after surgical treatment for T2 gallbladder carcinoma. Hepatogastroenterology 51, 1609\u20131611 (2004).","journal-title":"Hepatogastroenterology"},{"key":"48099_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3857\/roj.2017.00388","volume":"35","author":"TG Kim","year":"2017","unstructured":"Kim, T. G. Patterns of initial failure after resection for gallbladder cancer: implications for adjuvant radiotherapy. Radiat Oncol J 35, 359\u2013367, https:\/\/doi.org\/10.3857\/roj.2017.00388 (2017).","journal-title":"Radiat Oncol J"},{"key":"48099_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jso.21544","volume":"102","author":"SY Cho","year":"2010","unstructured":"Cho, S. Y. et al. Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol 102, 87\u201393, https:\/\/doi.org\/10.1002\/jso.21544 (2010).","journal-title":"J Surg Oncol"},{"key":"48099_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/jso.21141","volume":"98","author":"A Duffy","year":"2008","unstructured":"Duffy, A. et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol 98, 485\u2013489, https:\/\/doi.org\/10.1002\/jso.21141 (2008).","journal-title":"J Surg Oncol"},{"key":"48099_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.surg.2013.06.001","volume":"155","author":"O Hyder","year":"2014","unstructured":"Hyder, O. et al. Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched Surveillance, Epidemiology, and End Results analysis. Surgery 155, 85\u201393, https:\/\/doi.org\/10.1016\/j.surg.2013.06.001 (2014).","journal-title":"Surgery"},{"key":"48099_CR10","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s10620-005-3040-8","volume":"50","author":"H Itoh","year":"2005","unstructured":"Itoh, H. et al. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig Dis Sci 50, 2231\u20132242, https:\/\/doi.org\/10.1007\/s10620-005-3040-8 (2005).","journal-title":"Dig Dis Sci"},{"key":"48099_CR11","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1245\/s10434-016-5262-8","volume":"23","author":"Y Kim","year":"2016","unstructured":"Kim, Y. et al. Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. Ann Surg Oncol 23, 2998\u20133008, https:\/\/doi.org\/10.1245\/s10434-016-5262-8 (2016).","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"48099_CR12","doi-asserted-by":"publisher","first-page":"djw202","DOI":"10.1093\/jnci\/djw202","volume":"109","author":"Kalyan C. Mantripragada","year":"2016","unstructured":"Mantripragada, K. C., Hamid, F., Shafqat, H. & Olszewski, A. J. Adjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base. J Natl Cancer Inst 109, https:\/\/doi.org\/10.1093\/jnci\/djw202 (2017).","journal-title":"Journal of the National Cancer Institute"},{"key":"48099_CR13","doi-asserted-by":"publisher","unstructured":"Mitin, T., Enestvedt, C. K., Jemal, A. & Sineshaw, H. M. Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival. J Natl Cancer Inst 109, https:\/\/doi.org\/10.1093\/jnci\/djw324 (2017).","DOI":"10.1093\/jnci\/djw324"},{"key":"48099_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000322914","volume":"79","author":"HS Park","year":"2010","unstructured":"Park, H. S. et al. Outcome of adjuvant therapy for gallbladder cancer. Oncology 79, 168\u2013173, https:\/\/doi.org\/10.1159\/000322914 (2010).","journal-title":"Oncology"},{"key":"48099_CR15","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1200\/JCO.2010.33.8020","volume":"29","author":"SJ Wang","year":"2011","unstructured":"Wang, S. J. et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 29, 4627\u20134632, https:\/\/doi.org\/10.1200\/JCO.2010.33.8020 (2011).","journal-title":"J Clin Oncol"},{"key":"48099_CR16","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/cncr.10831","volume":"95","author":"T Takada","year":"2002","unstructured":"Takada, T. et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95, 1685\u20131695, https:\/\/doi.org\/10.1002\/cncr.10831 (2002).","journal-title":"Cancer"},{"key":"48099_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijrobp.2008.10.052","volume":"75","author":"DG Gold","year":"2009","unstructured":"Gold, D. G. et al. Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys 75, 150\u2013155, https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.052 (2009).","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"48099_CR18","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"33","author":"E Ben-Josef","year":"2015","unstructured":"Ben-Josef, E. et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol 33, 2617\u20132622, https:\/\/doi.org\/10.1200\/JCO.2014.60.2219 (2015).","journal-title":"J Clin Oncol"},{"key":"48099_CR19","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan, A. M., Amir, E., Walter, T. & Knox, J. J. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 30, 1934\u20131940, https:\/\/doi.org\/10.1200\/JCO.2011.40.5381 (2012).","journal-title":"J Clin Oncol"},{"key":"48099_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.suc.2018.12.008","volume":"99","author":"L Hickman","year":"2019","unstructured":"Hickman, L. & Contreras, C. Gallbladder Cancer: Diagnosis, Surgical Management, and Adjuvant Therapies. Surg Clin North Am 99, 337\u2013355, https:\/\/doi.org\/10.1016\/j.suc.2018.12.008 (2019).","journal-title":"Surg Clin North Am"},{"key":"48099_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.21037\/jgo.2018.09.10","volume":"10","author":"S Kumar","year":"2019","unstructured":"Kumar, S. et al. Multimodality management of incidentally detected gall bladder cancer: long term results from a tertiary care cancer centre. J Gastrointest Oncol 10, 128\u2013133, https:\/\/doi.org\/10.21037\/jgo.2018.09.10 (2019).","journal-title":"J Gastrointest Oncol"},{"key":"48099_CR22","doi-asserted-by":"publisher","unstructured":"Manterola, C. et al. A systematic review of the effectiveness of adjuvant therapy for patients with gallbladder cancer. HPB (Oxford), https:\/\/doi.org\/10.1016\/j.hpb.2019.02.019 (2019).","DOI":"10.1016\/j.hpb.2019.02.019"},{"key":"48099_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38396-4","volume":"9","author":"S Zhu","year":"2019","unstructured":"Zhu, S. et al. Preoperative platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as predictors of clinical outcome in patients with gallbladder cancer. Sci Rep 9, 1823, https:\/\/doi.org\/10.1038\/s41598-018-38396-4 (2019).","journal-title":"Sci Rep"},{"issue":"5","key":"48099_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"John N Primrose","year":"2019","unstructured":"Primrose, J. N. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol, https:\/\/doi.org\/10.1016\/S1470-2045(18)30915-X (2019).","journal-title":"The Lancet Oncology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48099-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48099-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48099-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:29:46Z","timestamp":1671280186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48099-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48099"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48099-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"assertion":[{"value":"22 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11770"}}